Logiscreen

Insight Molecular Diagnostics Inc

$5.24
Market Cap 168.56M
ROE 380.8%
Gross Margin 46.9%
Debt/Equity -0.3
Current Ratio 2.5
Revenue QoQ -98.5%
EPS QoQ -0.5%
F-Score 3

About

Oncocyte Corporation is a molecular diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics & Research

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-4.40
vs median 33.61
P/B
-19.71
vs median 2.16
ROE
3.81
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics